Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,039 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID.
Bouhnik Y, Pineton de Chambrun G, Lambert J, Nachury M, Seksik P, Altwegg R, Vuitton L, Stefanescu C, Nancey S, Aubourg A, Serrero M, Filippi J, Desseaux K, Viennot S, Abitbol V, Boualit M, Bourreille A, Giletta C, Buisson A, Roblin X, Dib N, Malamut G, Amiot A, Fumery M, Louis E, Elgharabawy Y, Peyrin-Biroulet L; MICA-GETAID Study Group. Bouhnik Y, et al. Clin Gastroenterol Hepatol. 2023 Dec;21(13):3365-3378.e5. doi: 10.1016/j.cgh.2023.01.013. Epub 2023 Jan 31. Clin Gastroenterol Hepatol. 2023. PMID: 36731588 Free article.
Etrasimod for the treatment of ulcerative colitis.
Wils P, Peyrin-Biroulet L. Wils P, et al. Immunotherapy. 2023 Apr;15(5):311-321. doi: 10.2217/imt-2022-0255. Epub 2023 Feb 15. Immunotherapy. 2023. PMID: 36789612 Review.
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study.
Martin A, Nachury M, Peyrin-Biroulet L, Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D, Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, Altwegg R, Dib N, Pineton de Chambrun G, Savoye G, Carbonnel F, Viennot S, Amiot A; GETAID-Vedo-STOP Study Group. Martin A, et al. J Crohns Colitis. 2020 Jul 30;14(7):896-903. doi: 10.1093/ecco-jcc/jjaa005. J Crohns Colitis. 2020. PMID: 31930285 Free article.
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
Rayer C, Nachury M, Bourreille A, Roblin X, Peyrin-Biroulet L, Viennot S, Flamant M, Laharie D, Caron B, Dewitte M, Siproudhis L, Fumery M, Bouguen G. Rayer C, et al. BMC Gastroenterol. 2023 Feb 2;23(1):31. doi: 10.1186/s12876-022-02636-9. BMC Gastroenterol. 2023. PMID: 36732693 Free PMC article. No abstract available.
Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study.
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, Meyer A, Nachury M, Laharie D, Le Berre C, Guillo L, Biron A, Caillo L, Buisson A, Nancey S, Uzzan M, Vuitton L, Gilletta C, Geyl S, Blain A, Kirchgesner J, Ah-Soune P, Duveau N, Vidon M, Abitbol V, Paupard T, Tran-Minh ML, Defrance A, Peyrin-Biroulet L. Fumery M, et al. Among authors: peyrin biroulet l. Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00423-3. doi: 10.1016/j.cgh.2024.04.016. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38729389
Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials.
Vuyyuru SK, Ma C, Nguyen TM, Zou G, Peyrin-Biroulet L, Danese S, Dulai P, Narula N, Singh S, Jairath V. Vuyyuru SK, et al. Among authors: peyrin biroulet l. EClinicalMedicine. 2024 May 4;72:102621. doi: 10.1016/j.eclinm.2024.102621. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38726222 Free PMC article.
1,039 results